Stanley Twarog - Profile and Investment Details

Investor Profile

Stanley Twarog is a Venture Capital, Private Equity Firm based in New York City, New York, United States with a diverse investment portfolio that includes companies such as HNI Healthcare, Navidea Biopharmaceuticals, Astute Medical, T2 Biosystems, TriVascular, Ceterix Orthopaedics, Omeros, Benvenue Medical, AFT Pharmaceuticals, Outset Medical, Good Start Genetics, BioDelivery Sciences International, Valeritas, Intrinsic TherapeuticsNanoString Technologies, Endoceutics, Harmony Biosciences, GenomeDx Biosciences, Bioniche Pharma Group, Blue Belt Technologies, TearLab Corporation, Exagen, Nevro, Avinger, Strongbridge Biopharma, SOC Telemed, Solta Medical, Corium International, Iroko Pharmaceuticals, Cardiome Pharma, ViewRay, Synergy Pharmaceuticals, Autonomic Technologies, EndoGastric Solutions, US WorldMeds, Biodesix, Silk Road Medical, Tandem Diabetes Care, RainDance Technologies, Earlens Corporation, Hicuity Health, Inc., . Over time, Stanley Twarog has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Stanley Twarog is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Hospitals, Wellness, Women Founded, Equities, Healthcare Innovation, Telemedicine, Portfolio Management, Medical Technologies, Finance, Biotechnology, Healthcare IT, Medical Devices, Consulting, Health Diagnostics, Regulatory Compliance, Medical, Big Data, B2B, Financial Advisory, Media and Entertainment, Pharmaceuticals may find it worthwhile to explore potential connections with Stanley Twarog, as their portfolio suggests a familiarity and interest in this area.

Understanding Stanley Twarog’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.